ECSP21067052A - Formulación sólida del modulador de ensamblaje de la cápside - Google Patents
Formulación sólida del modulador de ensamblaje de la cápsideInfo
- Publication number
- ECSP21067052A ECSP21067052A ECSENADI202167052A ECDI202167052A ECSP21067052A EC SP21067052 A ECSP21067052 A EC SP21067052A EC SENADI202167052 A ECSENADI202167052 A EC SENADI202167052A EC DI202167052 A ECDI202167052 A EC DI202167052A EC SP21067052 A ECSP21067052 A EC SP21067052A
- Authority
- EC
- Ecuador
- Prior art keywords
- capsid assembly
- solid formulation
- assembly modulator
- modulator
- capsid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La presente divulgación se refiere a formas farmacéuticas orales sólidas un inhibidor de ensamblaje de la cápside para el tratamiento de la infección por el virus de la hepatitis B.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/352,754 US10973801B2 (en) | 2018-03-14 | 2019-03-13 | Capsid assembly modulator dosing regimen |
PCT/IB2019/000231 WO2019175657A1 (en) | 2018-03-14 | 2019-03-13 | Capsid assembly modulator dosing regimen |
EP2019056348 | 2019-03-13 | ||
EP19197566 | 2019-09-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP21067052A true ECSP21067052A (es) | 2021-11-18 |
Family
ID=72427202
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ECSENADI202167052A ECSP21067052A (es) | 2019-03-13 | 2021-09-10 | Formulación sólida del modulador de ensamblaje de la cápside |
Country Status (16)
Country | Link |
---|---|
EP (1) | EP3937928A1 (es) |
JP (1) | JP2022524819A (es) |
KR (1) | KR20210137484A (es) |
CN (1) | CN113557016A (es) |
AU (1) | AU2020235442A1 (es) |
BR (1) | BR112021017525A2 (es) |
CA (1) | CA3132095A1 (es) |
CR (1) | CR20210481A (es) |
EC (1) | ECSP21067052A (es) |
IL (1) | IL286209A (es) |
JO (1) | JOP20210250A1 (es) |
MA (1) | MA55280A (es) |
MX (1) | MX2021011030A (es) |
PE (1) | PE20212107A1 (es) |
SG (1) | SG11202109710QA (es) |
WO (1) | WO2020183020A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2019511542A (ja) | 2016-04-15 | 2019-04-25 | ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー | カプシド集合阻害剤を含む組み合わせ及び方法 |
US10973801B2 (en) * | 2018-03-14 | 2021-04-13 | Janssen Sciences Ireland Unlimited Company | Capsid assembly modulator dosing regimen |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JO3603B1 (ar) | 2013-05-17 | 2020-07-05 | Janssen Sciences Ireland Uc | مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي |
US10973801B2 (en) * | 2018-03-14 | 2021-04-13 | Janssen Sciences Ireland Unlimited Company | Capsid assembly modulator dosing regimen |
-
2020
- 2020-03-13 PE PE2021001464A patent/PE20212107A1/es unknown
- 2020-03-13 EP EP20709618.1A patent/EP3937928A1/en not_active Withdrawn
- 2020-03-13 JO JOP/2021/0250A patent/JOP20210250A1/ar unknown
- 2020-03-13 MA MA055280A patent/MA55280A/fr unknown
- 2020-03-13 MX MX2021011030A patent/MX2021011030A/es unknown
- 2020-03-13 BR BR112021017525A patent/BR112021017525A2/pt not_active IP Right Cessation
- 2020-03-13 AU AU2020235442A patent/AU2020235442A1/en not_active Abandoned
- 2020-03-13 JP JP2021554750A patent/JP2022524819A/ja active Pending
- 2020-03-13 SG SG11202109710Q patent/SG11202109710QA/en unknown
- 2020-03-13 CR CR20210481A patent/CR20210481A/es unknown
- 2020-03-13 CA CA3132095A patent/CA3132095A1/en not_active Abandoned
- 2020-03-13 KR KR1020217031285A patent/KR20210137484A/ko unknown
- 2020-03-13 CN CN202080020501.XA patent/CN113557016A/zh active Pending
- 2020-03-13 WO PCT/EP2020/056991 patent/WO2020183020A1/en unknown
-
2021
- 2021-09-09 IL IL286209A patent/IL286209A/en unknown
- 2021-09-10 EC ECSENADI202167052A patent/ECSP21067052A/es unknown
Also Published As
Publication number | Publication date |
---|---|
KR20210137484A (ko) | 2021-11-17 |
WO2020183020A1 (en) | 2020-09-17 |
CN113557016A (zh) | 2021-10-26 |
SG11202109710QA (en) | 2021-10-28 |
CR20210481A (es) | 2021-10-25 |
MX2021011030A (es) | 2021-10-13 |
PE20212107A1 (es) | 2021-11-04 |
JP2022524819A (ja) | 2022-05-10 |
JOP20210250A1 (ar) | 2023-01-30 |
CA3132095A1 (en) | 2020-09-17 |
AU2020235442A1 (en) | 2021-08-12 |
MA55280A (fr) | 2022-01-19 |
IL286209A (en) | 2021-10-31 |
EP3937928A1 (en) | 2022-01-19 |
BR112021017525A2 (pt) | 2021-11-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2021000227A1 (es) | Regimen posologico del modulador del ensamblaje de la capside. (divisional de solicitud 2254-2020) | |
CL2019000415A1 (es) | Compuestos terapéuticos útiles para el tratamiento profiláctico o terapéuticos de una infección por el virus del vih. | |
CR20150454A (es) | Compuestos amida para el tratamiento de vih | |
ECSP20020410A (es) | Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp-1) y usos de los mismos | |
UY37252A (es) | Compuestos para el tratamiento de infección por virus de la hepatitis b | |
UY37581A (es) | Compuestos para el tratamiento de la infección por virus de la hepatitis b | |
CL2019002204A1 (es) | Compuestos inhibidores del vih. | |
CL2017001798A1 (es) | Compuestos de pirazina para el tratamiento de enfermedades infecciosas. | |
CL2018001996A1 (es) | Composiciones y métodos para modular la expresión del factor b del complemento (divisional de solicitud 2764-16) | |
CO2018000660A2 (es) | Compuestos derivados del (3β)-cholest-5-en-3-alquil-3-ol y (3β)-cholest-3-alquil-3-ol | |
CO2018000589A2 (es) | Oxiesteroles y composiciones farmacéuticas que los contienen | |
ECSP21067052A (es) | Formulación sólida del modulador de ensamblaje de la cápside | |
CL2012001959A1 (es) | Compuestos derivados del acido tiofeno-2-carboxilico, inhibidores de virus flaviviridae; composicion farmaceutica que los comprende; y su uso para el tratamiento de una infeccion viral por flaviviridae. | |
CL2018001199A1 (es) | Composiciones terapéuticas para el tratamiento del virus de inmunodeficiencia humana | |
CL2020000487A1 (es) | Agentes antivirales contra la hepatitis b. | |
CO2019009215A2 (es) | Sal hemi-sulfato de nucleótido para el tratamiento del virus de la hepatitis c | |
UY33897A (es) | Inhibidores del virus de la hepatitis c | |
CL2014000393A1 (es) | Compuestos derivados de benzofurano y sus sales, como inhibidores del virus de hepatitis c; composicion farmaceutica que los comprende; y su uso para el tratamiento o la prevencion de una infeccion por el virus de hepatitis c o de una enfermedad asociada con dicha infeccion. | |
UY34066A (es) | Inhibidores del virus de la hepatitis c | |
CL2020001358A1 (es) | Cepa vacunal de brucella modificada para el tratamiento de brucelosis | |
UY37166A (es) | Nucleósidos ánalogos de alquinilo como inhibidores de rinovirus humano | |
EA201890818A1 (ru) | Режим комбинированной терапии для лечения hcv | |
AR111017A1 (es) | Sal hemisulfato de un compuesto nucleotídico para el tratamiento del virus de la hepatitis c | |
AR109364A1 (es) | Compuestos antivirales | |
PL409016A1 (pl) | N-sulfonowa pochodna polialliloaminy, zastosowanie N-sulfonowej pochodnej polialliloaminy jako leku, zwłaszcza do profilaktyki i leczenia infekcji wirusem grypy typu A (IAV) oraz kompozycja farmaceutyczna zawierająca N-sulfonową pochodną polialliloaminy |